Stephanie R Land1, Farzana L Walcott2, Qing Liu2, D Lawrence Wickerham2, Joseph P Costantino2, Patricia A Ganz2. 1. National Surgical Adjuvant Breast and Bowel Project (now a part of NRG Oncology), Pittsburgh, PA (SRL, DLW, PAG); Division of Cancer Control and Population Sciences (SRL) and Division of Cancer Prevention (FLW), National Cancer Institute, Rockville, MD; NRG Oncology, Pittsburgh, PA and Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA (QL, JPC); Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA (DLW); UCLA Schools of Medicine and Public Health, and Jonsson Comprehensive Cancer Center, Division of Cancer Prevention & Control Research, Department of Health Services, Los Angeles, CA (PAG). stephanie.land@nih.gov. 2. National Surgical Adjuvant Breast and Bowel Project (now a part of NRG Oncology), Pittsburgh, PA (SRL, DLW, PAG); Division of Cancer Control and Population Sciences (SRL) and Division of Cancer Prevention (FLW), National Cancer Institute, Rockville, MD; NRG Oncology, Pittsburgh, PA and Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA (QL, JPC); Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA (DLW); UCLA Schools of Medicine and Public Health, and Jonsson Comprehensive Cancer Center, Division of Cancer Prevention & Control Research, Department of Health Services, Los Angeles, CA (PAG).
Abstract
BACKGROUND:Tamoxifen provides a 50% reduction in the incidence of breast cancer (BC) among high-risk women, yet many do not adhere to the five-year course of therapy. Using the prospective double-blind National Surgical Adjuvant Breast and Bowel Project P-1 study, we evaluated whether participant-reported outcomes were associated with drug adherence and whether baseline behavioral risk factors modified those associations. METHODS: P-1 participants were randomly assigned to placebo vs tamoxifen (20mg/day). Mixed effects logistic regression was used to evaluate whether baseline or three-month SF-36 quality of life (QOL) mental and physical component summaries (MCS, PCS), and participant-reported symptoms (gynecologic, vasomotor, sexual, and other) predicted 12-month drug adherence (76-100% of assigned medication). The evaluation accounted for age, treatment, estimated breast cancer risk, education, baseline smoking, alcohol consumption, and obesity. All statistical tests were two-sided. RESULTS:Participants enrolled at least three years before trial unblinding and without medically indicated discontinuation before 12 months were eligible for the present analyses (n = 10 576). At 12 months, 84.3% were adherent. Statistically significant predictors of adherence were: three-month MCS (odds ratio [OR] = 1.15 per 10 points, 95% confidence interval [CI] = 1.06 to 1.25); three-month gynecologic symptoms among moderate alcohol drinkers (OR = .79, 95% CI = 0.72 to 0.88); baseline vasomotor symptoms among participants assigned tamoxifen (OR = .88, 95% CI = 0.80 to 0.97); and three-month sexual symptoms among younger participants (OR = .89 at age 41 years, 95% CI = 0.80 to 0.99). The strongest association was with three-month other symptoms (OR = .77, 95% CI = 0.63 to 0.93). PCS was not associated with adherence. Symptom and QOL associations were not modified by smoking or obesity. CONCLUSIONS: Promoting QOL and managing symptoms early in therapy may be important strategies to improve adherence. Published by Oxford University Press 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
RCT Entities:
BACKGROUND:Tamoxifen provides a 50% reduction in the incidence of breast cancer (BC) among high-risk women, yet many do not adhere to the five-year course of therapy. Using the prospective double-blind National Surgical Adjuvant Breast and Bowel Project P-1 study, we evaluated whether participant-reported outcomes were associated with drug adherence and whether baseline behavioral risk factors modified those associations. METHODS: P-1 participants were randomly assigned to placebo vs tamoxifen (20mg/day). Mixed effects logistic regression was used to evaluate whether baseline or three-month SF-36 quality of life (QOL) mental and physical component summaries (MCS, PCS), and participant-reported symptoms (gynecologic, vasomotor, sexual, and other) predicted 12-month drug adherence (76-100% of assigned medication). The evaluation accounted for age, treatment, estimated breast cancer risk, education, baseline smoking, alcohol consumption, and obesity. All statistical tests were two-sided. RESULTS:Participants enrolled at least three years before trial unblinding and without medically indicated discontinuation before 12 months were eligible for the present analyses (n = 10 576). At 12 months, 84.3% were adherent. Statistically significant predictors of adherence were: three-month MCS (odds ratio [OR] = 1.15 per 10 points, 95% confidence interval [CI] = 1.06 to 1.25); three-month gynecologic symptoms among moderate alcohol drinkers (OR = .79, 95% CI = 0.72 to 0.88); baseline vasomotor symptoms among participants assigned tamoxifen (OR = .88, 95% CI = 0.80 to 0.97); and three-month sexual symptoms among younger participants (OR = .89 at age 41 years, 95% CI = 0.80 to 0.99). The strongest association was with three-month other symptoms (OR = .77, 95% CI = 0.63 to 0.93). PCS was not associated with adherence. Symptom and QOL associations were not modified by smoking or obesity. CONCLUSIONS: Promoting QOL and managing symptoms early in therapy may be important strategies to improve adherence. Published by Oxford University Press 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Andrew N Freedman; Barry I Graubard; Sowmya R Rao; Worta McCaskill-Stevens; Rachel Ballard-Barbash; Mitchell H Gail Journal: J Natl Cancer Inst Date: 2003-04-02 Impact factor: 13.506
Authors: M H Gail; J P Costantino; J Bryant; R Croyle; L Freedman; K Helzlsouer; V Vogel Journal: J Natl Cancer Inst Date: 1999-11-03 Impact factor: 13.506
Authors: A Guerrieri-Gonzaga; L Baglietto; H Johansson; B Bonanni; C Robertson; M T Sandri; L Canigiula; C Lampreda; S Diani; E A Lien; A Decensi Journal: Cancer Epidemiol Biomarkers Prev Date: 2001-09 Impact factor: 4.254
Authors: M H Gail; L A Brinton; D P Byar; D K Corle; S B Green; C Schairer; J J Mulvihill Journal: J Natl Cancer Inst Date: 1989-12-20 Impact factor: 13.506
Authors: B Fisher; J P Costantino; D L Wickerham; C K Redmond; M Kavanah; W M Cronin; V Vogel; A Robidoux; N Dimitrov; J Atkins; M Daly; S Wieand; E Tan-Chiu; L Ford; N Wolmark Journal: J Natl Cancer Inst Date: 1998-09-16 Impact factor: 13.506
Authors: Mikael Eriksson; Martin Eklund; Signe Borgquist; Roxanna Hellgren; Sara Margolin; Linda Thoren; Ann Rosendahl; Kristina Lång; José Tapia; Magnus Bäcklund; Andrea Discacciati; Alessio Crippa; Marike Gabrielson; Mattias Hammarström; Yvonne Wengström; Kamila Czene; Per Hall Journal: J Clin Oncol Date: 2021-03-18 Impact factor: 50.717
Authors: Cole B Haskins; Bradley D McDowell; Ryan M Carnahan; Jess G Fiedorowicz; Robert B Wallace; Brian J Smith; Elizabeth A Chrischilles Journal: Breast Cancer Res Treat Date: 2018-11-21 Impact factor: 4.624
Authors: Rachael Jane Thorneloe; Rob Horne; Lucy Side; Michael Scott Wolf; Samuel George Smith Journal: Clin Breast Cancer Date: 2018-12-03 Impact factor: 3.225
Authors: Carmen Wing Han Chan; Christine Miaskowski; Alexandra McCarthy; Mary Miu Yee Waye; Winnie Yeo; Winnie Kwok Wai So; Kai Chow Choi; Stephen Kwok Wing Tsui; Judy Yuet Wa Chan Journal: Medicine (Baltimore) Date: 2020-02 Impact factor: 1.817